Trial Profile
Pharmacokinetic and safety study cobicistat-boosted elvitegravir in subjects with hepatic impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Elvitegravir (Primary) ; Cobicistat
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 03 Dec 2015 New trial record